Skip to content
Review Open access

Association between serum perfluoroalkyl substances and COPD risk: population evidence and in vitro validation.

Jul 2026 · BMC Pulmonary Medicine · 0 citations
Medicine

TL;DR

Mixture exposure showed a significant positive association with chronic obstructive pulmonary disease risk, and these substances disrupt pulmonary homeostasis through concurrent molecular activation and lipid-metabolic disturbance, evidenced by triglyceride-glucose index mediation.

Abstract

Background

Per- and polyfluoroalkyl substances are characterized by environmental persistence, bioaccumulation potential, and multi-organ toxicity. Given their ubiquitous presence in the environment and human serum, concerns regarding respiratory health risks are growing, particularly due to scarce evidence on environmental etiologies of chronic obstructive pulmonary disease in never-smokers. This study aimed to investigate the mechanistic role of these substances in chronic obstructive pulmonary disease through a population-computational-experimental paradigm, with specific focus on lipid-metabolic mediation.

Methods

Data from the National Health and Nutrition Examination Survey (2007-2018) were analyzed using weighted quantile sum regression and quantile-based g-computation to assess mixture exposure effects. Mediation analysis was performed to evaluate the triglyceride-glucose index as a metabolic intermediate pathway. Network toxicology and molecular docking analyses were conducted to identify core protein targets. Human bronchial epithelial cells were exposed to perfluorooctanoic acid to validate target gene expression and downstream pathway activation.

Results

Mixture exposure showed a significant positive association with chronic obstructive pulmonary disease risk. Perfluorooctanesulfonic acid and perfluorooctanoic acid were the primary toxicity contributors. The association remained robust among never-smokers. The triglyceride-glucose index significantly mediated the exposure-disease relationship (mediation proportion: 6.6%-7.8%). SRC, EGFR, PPARG, and MMP9 were identified as core targets. Experimental validation confirmed that perfluorooctanoic acid altered expression of these targets, activating inflammation and remodeling pathways.

Conclusions

These substances disrupt pulmonary homeostasis through concurrent molecular activation and lipid-metabolic disturbance, evidenced by triglyceride-glucose index mediation. This dual mechanism provides new evidence for chronic obstructive pulmonary disease prevention in never-smokers and identifies potential metabolic intervention targets.

Read PDF

Similar papers

Aug 2026

Organophosphate flame retardants and incident type 2 diabetes: Integrating population evidence, mechanistic insights, and effect modification by healthy lifestyle.

Mixed OPFRs exposure, dominated by TPHP, was associated with higher incident T2DM risk, partly attenuated by healthier lifestyle trajectories, supporting combined exposure-reduction and lifestyle-based prevention strategies.

Xueyan Wu, Yilin Zhou, Yue Nie et al. · 0 citations
Open access Jul 2026

Per- and Polyfluoroalkyl Substances Exposure in New Jersey Prostate Cancer Survivors: A Pilot Biomonitoring Study

This pilot study provides some of the first estimates of PFAS exposure among prostate cancer patients in serum and tap water, showing moderate correlations between tap water and serum concentrations of specific PFAS analytes.

Stefanie A. Joseph, Chidinma Opara, Megan R. Shanahan et al. · 0 citations
Open access Jul 2026

PM2.5 chemical constituents and chronic obstructive pulmonary disease mortality risk: The Pearl River Cohort study.

These findings underscore the potential contribution of individual PM2.5 constituents and their mixtures in COPD mortality, while suggesting actionable source-control priorities and coordinated precursor-reduction strategies, as well as population-specific prevention approaches.

Luxin Zheng, Yixuan Yang, Wenjing Wu et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.